Melissa McGivney, PharmD, FAPhA, FCCP, discusses her career journey from her local pharmacy to a national leadership role with the American Pharmacists Association.
|Articles|October 23, 2012
FDA approves perampanel as adjunctive treatment for partial-onset seizures in patients with epilepsy aged 12 years and older
FDA has approved perampanel (Fycompa, Eisai), an AMPA receptor antagonist, as an adjunctive treatment of partial-onset seizures with or without secondarily generalized seizures in patients aged 12 years and older who have epilepsy.
Advertisement
Advertisement
Related to this article
Researchers evaluate peer-reviewed literature on interventions to improve vaccine uptake among thousands of US adults studied between 2010 and 2015.
Infectious disease readiness depends on rehearsed workflows, bidirectional public health communication, and rapid access to care.
Pharmacist pain clinics typically focus on comprehensive medication management involving the entire patient scenario.
A case shows a suspected recurrence of pneumococcal disease that ended with removal of one cochlear implant and replacement of the other.
Detailed phase 3 data show retatrutide lowered body weight and A1C over 80 weeks for patients with diabetes and obesity.
In celebration of the organization’s recent convention, NCPA released its annual digest report for members, providing a detailed overview of independent community pharmacy.
Local collaborations can turn pharmacies into care-coordination hubs, but lasting results require trained teams, shared data, and sustainable payment.
Advertisement
Advertisement
Trending on Drug Topics
1
Serotype 34 Causes Pneumococcal Meningitis in Child With Cochlear Implants
2
Addressing Medication Adherence in Cardiometabolic Health
3
From Binder to Action: Making Infectious Disease Outbreak Plans Operational
4
Retatrutide Delivers 20.8% Weight Loss in Adults With Type 2 Diabetes
5